| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 156.10 | 29.8% |
| Total Income | 156.10 | 29.8% |
| Expenditure | 145.60 | 15.5% |
| PBT | 13.40 | 85.5% |
| Net Profit | 6.80 | 90.0% |
| OPM | 6.73% | 15.73pp |
| NPM | 4.36% | 26.25pp |
| EPS | 0.13 | 89.6% |
Emergent BioSolutions Reports Q1 2026 Revenue of $156.1 Million
03 May 2026 · 3 May, 6:06 pm
Summary
Emergent BioSolutions reported a strong start to 2026 with first quarter revenues of $156.1 million, exceeding the high end of their guidance range. Net income was $6.8 million, with an adjusted EBITDA of $35.6 million. The company has been actively strengthening its financial position through debt refinancing and strategic manufacturing partnerships. They maintained their market share position with NARCAN® Nasal Spray and continued to deliver biodefense medical countermeasures to government partners. The company's financial forecast for full year 2026 includes total revenues between $720 million and $760 million.
Key Highlights
- 1
Emergent BioSolutions reported total revenues of $156.1 million for the first quarter of 2026.
- 2
The company's net income for Q1 2026 was $6.8 million, resulting in a net income margin of 4%.
- 3
Adjusted EBITDA for the first quarter of 2026 reached $35.6 million, with an adjusted EBITDA margin of 23%.
- 4
Revenues from Smallpox MCM products decreased by $42.2 million, or 40%, compared to Q1 2025, primarily due to lower ACAM2000® sales.
- 5
The company secured over $60 million in new contract awards with the U.S. Government and new orders with an international government partner for smallpox medical countermeasures.
- 6
Emergent refinanced its term loan with a new $150 million facility and amended its asset-backed loan facility.
- 7
The company's financial forecast for full year 2026 includes total revenues between $720 million and $760 million.
Management Comments
Joe Papa
Emergent’s first quarter results demonstrate a strong and positive start to 2026, with healthy topline revenue of $156 million, above the high-end of our guidance range, and adjusted EBITDA of $36 million. We are further strengthening our financial position in 2026 through our recently announced debt refinancing, which increases our strategic flexibility and meaningfully reduces interest expense payments. Additionally, we are pleased to have monetized our capability and capacity in our Canton facility by securing a strategic manufacturing partnership with Substipharm Biologics, which includes a manufacturing agreement and exclusive U.S. (future) distribution rights to its Japanese Encephalitis vaccine, following U.S. FDA approval. We maintained our market share position with NARCAN® Nasal Spray through our efforts across multiple distribution channels, as well as by launching a new carrying case and multipack presentations, and we continued to deliver our biodefense medical countermeasures to multiple government partners in the United States, Canada and around the world. Our mission to protect and save lives remains a prominent driving force for our entire team and we are proud to do so while executing our multi-year transformation plan and turnaround strategy to build several growing and profitable verticals over time.
Informational and educational content only. Not investment advice.